Demethylwedelolactone, a natural product isolated and purified from the herbs of Eclipta prostrata, has trypsin inhibitory effect. Demethylwedelolactone exerts anti-invasive growth effect on breast cancer cells.

GCN2-IN-1 is a potent general control nonderepressible 2 kinase (GCN2) inhibitor with IC50s of <0.3 μM in the enzyme and cell assay.

Fulacimstat is a chymase inhibitor with IC50 values of 4nM and 3 nM for human and hamster chymase enzyme, respectively.

UK-371804 is a potent and selective urokinase-type plasmogen activator (uPA) inhibitor with excellent enzyme potency (Ki=10 nM) and selectivity profile (4000-fold versus tPA and 2700-fold versus plasmin).

Bradykinin is a pro-inflammatory polypeptide. It is an important mediator of hyperalgesia, inflammatory diseases, asthma and cancer with anti-cancer activities. Targeting the bradykinin system by either blocking the bradykinin production may open a new potential therapeutic window for the treatment of COVID-19 induced acute respiratory distress syndrome (ARDS) particularly before patients enter the irreversible stages.

Avoralstat is an oral plasma kallikrein (PKK) inhibitor and is used for the treatment of hereditary angioedema.

Daclatasvir is a first-in-class, highly-selective oral HCV NS5A inhibitor.

MK-5172 inhibits Hepatitis C virus NS3/4a protease with Ki of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively.

Danoprevir, a peptidomimetic, is an inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2 nM - 3.5 nM.